TargetBeta
TNFRSF13B
TNF receptor superfamily member 13B · also TACI, CD267, IGAD2 · CD molecules
3 programs in company-led studies act on TNFRSF13B, from 3 companies: 2 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| telitaciceptrule | RemeGen | phase 3 | 258 running | – | NCIt |
| povetaciceptrule | Vertex Pharmaceuticals | phase 3 | 96 running | – | NCIt |
| SHR-2173 | Jiangsu HengRui Medicine | phase 2 | 86 running | IFNAR1 | the company's pipeline |
Also acted on by the same programs
Conditions their studies are in
- Glomerulonephritis, IGA, 3 programs
- Myasthenia Gravis, 3 programs
- Glomerulonephritis, Membranous, 2 programs
- Lupus Erythematosus, Systemic, 2 programs
- Purpura, Thrombocytopenic, Idiopathic, 2 programs
- Lupus Nephritis, 1 program
- Lymphoma, Follicular, 1 program
- Sjogren's Syndrome, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 31, 2026telitacicept · RemeGen · phase 3 · NCT07249632
- Apr 2027SHR-2173 · Jiangsu HengRui Medicine · phase 2 · NCT07354932
- Dec 12, 2027povetacicept · Vertex Pharmaceuticals · phase 3 · NCT07890909
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.